How we earn affiliate and referral compensation — and why it never changes our editorial scores or rankings.
SemaglutideGLPOne.com is an independent editorial publication that compares compounded semaglutide telehealth providers. To fund this work, we participate in affiliate and referral arrangements with some of the providers we cover. This page explains those arrangements in plain terms, in line with U.S. Federal Trade Commission (FTC) guidance on disclosing material connections.
When you click certain links on this site and subsequently enroll with a provider, we may receive referral compensation. NexLife is our Editor’s #1 Pick and is, among other providers we review, one from which we may earn referral compensation. Compensation never determines editorial scores: rankings are produced by applying our published six-pillar transparency rubric, and the editorial process is described on our editorial independence and conflicts of interest pages.
For a fuller explanation of our business model and revenue, see How we make money. For our methodology, see Methodology.
Medical note: This site is editorial and not medical advice. Compounded semaglutide is not FDA-approved; consult a licensed clinician.